Kite Pharma says it is looking to secondary suppliers and other risk mitigation measures to manage its cell therapy cold chain supply amid a growing production network. Since opening a 43,500 square-foot manufacturing plant in Santa Monica, California in 2016, Kite Pharma – and Gilead Sciences, which acquired the firm in October 2017 – has rapidly expanded its production network, to support supply of its chimeric antigen receptor (CAR) T-cell therapy Yescarta (axicabtagene ciloleucel). In May 2018, the firm opened a…